

Irina P Nikishina

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8063103/irina-p-nikishina-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

18
papers

669
citations

10
h-index

19
g-index

19
ext. papers

844
ext. citations

3.5
avg, IF

2.31
L-index

#	Paper	IF	Citations
18	Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1110-7	2.4	195
17	Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study. <i>Arthritis and Rheumatism</i> , 2007 , 57, 35-43		106
16	A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. <i>Arthritis and Rheumatism</i> , 2005 , 52, 563-72		68
15	Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 21-29	2.4	64
14	Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. <i>The Lancet Child and Adolescent Health</i> , 2019 , 3, 255-263	14.5	58
13	Development of the autoinflammatory disease damage index (ADDI). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 821-830	2.4	54
12	Comparable Efficacy of Abatacept Used as First-line or Second-line Biological Agent for Severe Juvenile Idiopathic Arthritis-related Uveitis. <i>Journal of Rheumatology</i> , 2016 , 43, 2068-2073	4.1	41
11	Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2016 , 43, 816-24	4.1	27
10	Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial. <i>Arthritis Research and Therapy</i> , 2019 , 21, 125	5.7	17
9	In silico validation of the Autoinflammatory Disease Damage Index. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1599-1605	2.4	17
8	Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial. <i>Journal of Rheumatology</i> , 2018 , 45, 1173-1179	4.1	6
7	Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial. <i>Clinical Rheumatology</i> , 2018 , 37, 1807-1816	3.9	5
6	SYSTEMIC LUPUS ERYTHEMATOSUS: CLINICAL RECOMMENDATIONS. PART 1. <i>Voprosy Sovremennoi Pediatrii - Current Pediatrics</i> , 2018 , 17, 19-37	0.5	4
5	Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1966-1975	9.5	4
4	SYSTEMIC LUPUS ERYTHEMATOSUS: CLINICAL RECOMMENDATIONS. PART 2. <i>Voprosy Sovremennoi Pediatrii - Current Pediatrics</i> , 2018 , 17, 110-125	0.5	2
3	Pulmonary Involvement in Systemic Onset Juvenile Arthritis: Current Status of the Problem. <i>Voprosy Sovremennoi Pediatrii - Current Pediatrics</i> , 2021 , 20, 31-37	0.5	1
2	The Russian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018 , 38, 339-346	3.6	

- 1 The Experience of Using a Combination of Febuxostat and Canakinumab in Tophaceous Gout Complicated by Chronic Kidney Disease in a Teenage Patient: A Case Study. *Voprosy Sovremennoi Pediatrii - Current Pediatrics*, **2018**, 17, 399-407 0.5